PL3463328T3 - Seladelpar do leczenia pierwotnego zapalenia dróg żółciowych - Google Patents

Seladelpar do leczenia pierwotnego zapalenia dróg żółciowych

Info

Publication number
PL3463328T3
PL3463328T3 PL17722943.2T PL17722943T PL3463328T3 PL 3463328 T3 PL3463328 T3 PL 3463328T3 PL 17722943 T PL17722943 T PL 17722943T PL 3463328 T3 PL3463328 T3 PL 3463328T3
Authority
PL
Poland
Prior art keywords
seladelpar
treatment
cholangitis
primary
primary cholangitis
Prior art date
Application number
PL17722943.2T
Other languages
English (en)
Polish (pl)
Inventor
Pol Boudes
Charles A. Mcwherter
Original Assignee
Cymabay Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics, Inc. filed Critical Cymabay Therapeutics, Inc.
Publication of PL3463328T3 publication Critical patent/PL3463328T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17722943.2T 2016-05-31 2017-04-26 Seladelpar do leczenia pierwotnego zapalenia dróg żółciowych PL3463328T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662343688P 2016-05-31 2016-05-31
PCT/US2017/029620 WO2017209865A1 (en) 2016-05-31 2017-04-26 Treatment of intrahepatic cholestatic diseases

Publications (1)

Publication Number Publication Date
PL3463328T3 true PL3463328T3 (pl) 2022-10-03

Family

ID=58699276

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17722943.2T PL3463328T3 (pl) 2016-05-31 2017-04-26 Seladelpar do leczenia pierwotnego zapalenia dróg żółciowych

Country Status (27)

Country Link
US (5) US10272058B2 (enExample)
EP (1) EP3463328B1 (enExample)
JP (1) JP7079735B2 (enExample)
KR (1) KR102408288B1 (enExample)
CN (1) CN109195594A (enExample)
AU (1) AU2017274293B2 (enExample)
BR (1) BR112018074147A2 (enExample)
CA (1) CA3024155C (enExample)
CY (1) CY1125465T1 (enExample)
DK (1) DK3463328T3 (enExample)
ES (1) ES2921230T3 (enExample)
HR (1) HRP20220903T1 (enExample)
HU (1) HUE059838T2 (enExample)
IL (1) IL263372B2 (enExample)
LT (1) LT3463328T (enExample)
MX (1) MX390417B (enExample)
NZ (1) NZ748721A (enExample)
PL (1) PL3463328T3 (enExample)
PT (1) PT3463328T (enExample)
RS (1) RS63345B1 (enExample)
RU (1) RU2765460C2 (enExample)
SG (1) SG11201810123SA (enExample)
SI (1) SI3463328T1 (enExample)
SM (1) SMT202200471T1 (enExample)
UA (1) UA122719C2 (enExample)
WO (1) WO2017209865A1 (enExample)
ZA (1) ZA201808360B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
HUE041733T2 (hu) 2014-03-20 2019-05-28 Cymabay Therapeutics Inc Intrahepatikus kolesztázisos betegségek kezelése
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
BR112021009038A2 (pt) * 2018-11-16 2021-08-10 Cymabay Therapeutics, Inc. tratamento combinado de nafld e nash
SI4225291T1 (sl) * 2021-02-01 2024-07-31 CymaBay Therapeutics, Inc., Zdravljenje holangiopatij s seladelparjem

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6222025B1 (en) 1995-03-06 2001-04-24 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
CA2749312A1 (en) 1996-02-14 1997-08-21 Novartis Ag Sugar-modified gapped oligonucleotides
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
CA2539446C (en) 2003-09-19 2013-12-03 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
DK1725234T4 (en) 2004-03-05 2016-05-09 Univ Pennsylvania METHODS OF TREATING DISEASES OR DISEASES CONNECTED WITH HYPERLIPIDEMIA AND HYPERCOLESTEROLYMIA WITH MINIMIZATION OF SIDE EFFECTS
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
MX2011004077A (es) 2008-10-17 2011-08-17 Metabolex Inc Metodos para reducir particulas de ldl densas, pequeñas.
NZ720946A (en) * 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2011123401A1 (en) 2010-03-30 2011-10-06 Novartis Ag Uses of dgat1 inhibitors
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2015077154A1 (en) 2013-11-20 2015-05-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
HUE041733T2 (hu) 2014-03-20 2019-05-28 Cymabay Therapeutics Inc Intrahepatikus kolesztázisos betegségek kezelése
WO2015157697A1 (en) 2014-04-11 2015-10-15 Cymabay Therapeutics, Inc. Treatment of nafld and nash
CN106470675A (zh) 2014-06-26 2017-03-01 西玛贝医药公司 严重高甘油三酯血症的治疗
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
AU2018342323B2 (en) 2017-09-26 2021-09-23 Cymabay Therapeutics, Inc. Treatment of cholestatic pruritus
CA3118965A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
BR112021009038A2 (pt) 2018-11-16 2021-08-10 Cymabay Therapeutics, Inc. tratamento combinado de nafld e nash

Also Published As

Publication number Publication date
MX2018014915A (es) 2019-04-24
US20170340589A1 (en) 2017-11-30
RU2018146504A3 (enExample) 2020-07-27
DK3463328T3 (da) 2022-07-04
MX390417B (es) 2025-03-20
RU2765460C2 (ru) 2022-01-31
ES2921230T3 (es) 2022-08-22
AU2017274293B2 (en) 2022-03-31
RU2018146504A (ru) 2020-07-09
US20210000774A1 (en) 2021-01-07
US11596614B2 (en) 2023-03-07
HUE059838T2 (hu) 2023-01-28
SMT202200471T1 (it) 2023-01-13
UA122719C2 (uk) 2020-12-28
LT3463328T (lt) 2022-08-10
US20190255004A1 (en) 2019-08-22
EP3463328B1 (en) 2022-06-15
CY1125465T1 (el) 2025-05-09
US10272058B2 (en) 2019-04-30
EP3463328A1 (en) 2019-04-10
PT3463328T (pt) 2022-07-07
SI3463328T1 (sl) 2022-08-31
BR112018074147A2 (pt) 2019-03-06
KR20190015363A (ko) 2019-02-13
IL263372A (en) 2018-12-31
CA3024155A1 (en) 2017-12-07
KR102408288B1 (ko) 2022-06-10
US20210220305A1 (en) 2021-07-22
HRP20220903T1 (hr) 2022-10-14
US10478411B2 (en) 2019-11-19
JP2019518022A (ja) 2019-06-27
IL263372B2 (en) 2023-06-01
NZ748721A (en) 2022-04-29
ZA201808360B (en) 2020-02-26
CN109195594A (zh) 2019-01-11
US10813895B2 (en) 2020-10-27
RS63345B1 (sr) 2022-07-29
US11000494B2 (en) 2021-05-11
WO2017209865A1 (en) 2017-12-07
SG11201810123SA (en) 2018-12-28
AU2017274293A1 (en) 2018-12-13
US20200061006A1 (en) 2020-02-27
CA3024155C (en) 2023-10-10
JP7079735B2 (ja) 2022-06-02

Similar Documents

Publication Publication Date Title
HUS2100037I1 (hu) Vegyületek gerinc eredetû izomsorvadás kezelésére
HUE064141T2 (hu) Azolopirimidin rákkal összefüggõ rendellenességek kezelésére
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
IL256209A (en) Novel cannabinoid combination therapies for multiple myeloma (mm)
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
IL263680A (en) Combination therapies
IL247452A0 (en) Compounds for treatment of complement mediated disorders
IL264143B (en) Processes for preparing olaparib
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
EP3601536A4 (en) TREATMENT PROCESSES
DK3851537T5 (da) Behandling af hyperbilirubinæmi
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
HUE059694T2 (hu) Készítmény rák kezelésére
HUE055263T2 (hu) 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
HUE063044T2 (hu) Anti-CD38 ellenanyagok akut limfoblasztos leukémia kezelésére
DK3148529T3 (da) Forbindelser til behandling af hjernecancer
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
BR112016022976A2 (pt) Métodos para o tratamento de hcv
IL256103B (en) Compositions and methods for treating celiac sprue disease
HUE060517T2 (hu) Immunhiányos betegség kezelésére szolgáló eljárások
HUE064604T2 (hu) Menotropin meddõség kezelésére
EP3597225A4 (en) TREATMENT PROCESS
DK3331610T3 (da) Midler til anvendelse til behandling af gliom
PL3463328T3 (pl) Seladelpar do leczenia pierwotnego zapalenia dróg żółciowych